Year: 2011 | Volumen: 48 # 4
Prevention and treatment of osteoporosis in prostate cancer.
Authors: Drnovsek M., Echín M., Ercolano M., Rubín Z.
Osteoporosis and bone fractures are frequently overlooked complications of androgen deprivation therapy in men with non-metastatic prostate cancer.
Several therapies commonly used in the treatment of prostate cancers, particularly in androgen deprivation therapy for prostate cancer, are associated with significant bone loss and with an increase in fracture risk. The use of bisphosphonates seems to attenuate bone loss, although the long-term impact remains unclear because of insufficient follow-up. Several agents, such as denosumab and toremifene, have shown to be promising in reducing fracture risk in these patients. Adjuvant endocrine therapy with androgen deprivation can be considered a risk factor for the development of osteopenia, osteoporosis, and bone fracture, which can be mitigated by appropriate bisphosphonate therapy. Clear identification of risk factors for osteoporosis in individual patients could help in decision-making about whether to initiate treatment with bisphosphonates in patients under androgen deprivation therapy. Patients need to be educated about this risk and other measures to avoid this complication, including lifestyle modifications that may benefit their general and bone health. Rev Argent Endocrinol Metab 48: 225-234, 2011
No financial conflicts of interest exist.
Key words: prostate cancer, treatment of androgen deprivation, osteoporosis